07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

Activa PC Neurostimulator: Clinical trial amended

Functional Neuromodulation said FDA approved to increase enrollment to up to 50 patients from 20 patients ages 55-80 years with mild AD in the double-blind, U.S. and Canadian ADvance trial evaluating deep-brain stimulation with the...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

Activa PC Neurostimulator update

Functional Neuromodulation began the double-blind, U.S. and Canadian ADvance trial to evaluate deep-brain stimulation with the Activa PC Neurostimulator in 20 patients ages 55-80 years with mild AD. Functional Neuromodulation has a license to use...